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Abstract
Background: Acute liver failure is associated with numerous systemic consequences including neurological
dysfunction, termed hepatic encephalopathy, which contributes to mortality and is a challenge to manage in the
clinic. During hepatic encephalopathy, microglia activation and neuroinflammation occur due to dysregulated cell
signaling and an increase of toxic metabolites in the brain. Fractalkine is a chemokine that is expressed primarily in
neurons and through signaling with its receptor CX3CR1 on microglia, leads to microglia remaining in a quiescent
state. Fractalkine is often suppressed during neuropathies that are characterized by neuroinflammation. However,
the expression and subsequent role of fractalkine on microglia activation and the pathogenesis of hepatic
encephalopathy due to acute liver failure is unknown.
Methods: Hepatic encephalopathy was induced in mice via injection of azoxymethane (AOM) or saline for controls.
Subsets of these mice were implanted with osmotic minipumps that infused soluble fractalkine or saline into the
lateral ventricle of the brain. Neurological decline and the latency to coma were recorded in these mice, and brain,
serum, and liver samples were collected. Neurons or microglia were isolated from whole brain samples using
immunoprecipitation. Liver damage was assessed using hematoxylin and eosin staining and by measuring
serum liver enzyme concentrations. Fractalkine and CX3CR1 expression were assessed by real-time PCR,
and proinflammatory cytokine expression was assessed using ELISA assays.
Results: Following AOM administration, fractalkine expression is suppressed in the cortex and in isolated neurons
compared to vehicle-treated mice. CX3CR1 is suppressed in isolated microglia from AOM-treated mice. Soluble
fractalkine infusion into the brain significantly reduced neurological decline in AOM-treated mice compared to
saline-infused AOM-treated mice. Infusion of soluble fractalkine into AOM-treated mice reduced liver damage,
lessened microglia activation, and suppressed expression of chemokine ligand 2, interleukin-6, and tumor
necrosis factor alpha compared to saline-infused mice.
Conclusions: These findings suggest that fractalkine-mediated signaling is suppressed in the brain following the
development of hepatic encephalopathy. Supplementation of AOM-treated mice with soluble fractalkine led to
improved outcomes, which identifies this pathway as a possible therapeutic target for the management of
hepatic encephalopathy following acute liver injury.
Keywords: Acute liver failure, Azoxymethane, CX3CL1, CX3CR1, CCL2
(Continued on next page)
* Correspondence: demorrow@medicine.tamhsc.edu
1Department of Internal Medicine, Texas A&M Health Science Center, College
of Medicine, Temple, TX, USA
2Central Texas Veterans Healthcare System, 1901 S. 1st Street, Building 205,
Temple, TX 76504, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
McMillin et al. Journal of Neuroinflammation  (2016) 13:198 
DOI 10.1186/s12974-016-0674-8
(Continued from previous page)
Abbreviations: ADAMs, A disintegrin and metalloproteinase proteins; ALT, Alanine aminotransferasase;
AOM, Azoxymethane; CCL2, Chemokine ligand 2; DAPI, 4′,6-Diamidino-2-phenylindole; ERK1/2, Extracellular
signal-regulated kinase 1/2; GLAST, Glutamate aspartate transporter; ICV, Intracerebroventricular; IL, Interleukin;
RT-PCR, Real-time PCR; sFKN, Soluble fractalkine; TNFα, Tumor necrosis factor-α
Background
Acute liver failure in Europe and the USA is caused
primarily by acetaminophen-induced drug toxicity but
can also be the result of viral hepatitis, toxin ingestion,
non-acetaminophen-induced drug toxicity, and numerous
other rare causative factors [1]. Following the development
of acute liver failure, a variety of extrahepatic complications
can develop including renal, respiratory, immunological,
and neurological dysfunction. Of these complications,
neurological dysfunction accounts for around 25 % of the
mortality associated with this disease state and remains a
significant challenge for clinical management of this disease
[2]. These neurological complications are termed hepatic
encephalopathy and have a variety of neuropsychiatric pre-
sentations from asymptomatic to severe cognitive decline
and coma with implications on liver transplant priority,
patient quality of life, and survival [3, 4].
A growing body of evidence implicates neuroinflam-
mation and microglia activation involvement with the
development of hepatic encephalopathy. Elevations of
the proinflammatory cytokines interleukin (IL)-1β, IL-6,
and tumor necrosis factor alpha (TNFα) are observed in
both patients and in rodent models of acute liver failure
[5, 6]. During hepatic encephalopathy, the use of anti-
inflammatory therapeutics, such as minocycline, has been
shown to reduce neuroinflammation and neurological dys-
function [7]. The production of pathogenic proinflamma-
tory cytokines in the brain is a consequence of microglia
activation, which can occur via a variety of signals includ-
ing signal transduction by chemokines. We have previously
shown that chemokine ligand 2 (CCL2) is one pathogenic
chemotactic cytokine that is elevated in neurons during
hepatic encephalopathy due to acute liver failure and con-
tributes to both microglia activation and the elevation of
IL-1β and IL-6 [8]. The receptors for CCL2 and other
chemokines are primarily localized to microglia in the
brain and therefore chemokine signaling is important in
initiating the activation of microglia during states of neuro-
inflammation. Together, this implicates neuroinflammation
and chemokine-signaling pathways as causative factors in
the progression of hepatic encephalopathy.
Fractalkine, also known as CX3CL1, is the only member
of the CX3C class of chemokines. In the brain, fractalkine
is highly expressed in neurons but can be induced in astro-
cytes if they are treated with TNFα or interferon-γ [9, 10].
Fractalkine in its native form is a transmembrane protein
that can be cleaved by cathepsin S or a disintegrin and
metalloproteinase proteins (ADAMs) [11, 12]. Upon cleav-
age, fractalkine is released in its soluble form that contains
the extracellular N-terminal chemokine domain. Soluble
fractalkine can then bind its receptor, CX3CR1, which is a
G-protein coupled receptor that is localized to microglia
and is thought to keep microglia in a quiescent state [9, 13].
Fractalkine/CX3CR1 signaling has been demonstrated in
numerous studies to dampen neuroinflammation, with
fractalkine signaling being shown to reduce IL-1β secretion
in lipopolysaccharide-treated microglia [14]. This has also
been shown in vivo as rats with cerebral ischemia adminis-
tered CX3CR1 siRNA were found to have increased micro-
glia activation and proinflammatory cytokine expression
compared to ischemic controls [15]. In addition to this,
in a variety of inflammatory conditions there is a recipro-
cal relationship between fractalkine and CCL2, though
whether these chemokines have a direct effect on each
other or are inversely affected by an extraneous signal is
unknown [16, 17].
At this time, there have been no studies investigating
fractalkine in the context of neuroinflammation associated
with hepatic encephalopathy. Therefore, the aims of this
study were to assess the expression of fractalkine and its
interaction with inflammatory signaling in a murine model
of hepatic encephalopathy due to acute liver failure and to
determine how fractalkine contributes to the neurological
complications associated with this disease state.
Methods
Materials
Fractalkine antibodies were purchased from Abcam
(Cambridge, MA). Antibodies against IBA1 were purchased
from Wako Chemicals USA (Richmond, VA). NeuN
antibodies were ordered from Millipore (Billerica, MA).
Antibodies against CD11b and glutamate aspartate trans-
porter (GLAST) were purchased from Miltenyi Biotec (San
Diego, CA). Phosphorylated and total extracellular signal-
regulated kinase 1/2 (pERK1/2 and tERK1/2) antibodies
were purchased from Cell Signaling (Danvers, MA). Mouse
soluble fractalkine was purchased from R&D Systems
(Minneapolis, MN). Mouse fracktalkine, CCL2, IL-6, and
TNFα ELISAs were purchased from R&D Systems. All
real-time PCR (RT-PCR) primers were purchased from
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SABiosciences (Frederick, MD). Total bilirubin was assayed
using an ELISA kit from Cusabio (Wuha, China). All other
chemicals and reagents were purchased from Sigma-
Aldrich (St. Louis, MO) unless otherwise noted and were of
the highest grade available.
Mouse model of hepatic encephalopathy
Male C57Bl/6 mice (20–25 g; Charles River Laboratories,
Wilmington, MA) were used in all in vivo experiments
using methodology described previously [8, 18, 19]. All
animal experiments were performed following approval
from Baylor Scott & White Health Institutional Animal
Care and Use Committee (Temple, TX). Mice were pro-
vided free access to water and rodent chow and were
housed in constant temperature, humidity, and 12-h light-
dark cycling. Acute liver failure was induced via a single
intraperitoneal injection of 100 mg/kg of azoxymethane
(AOM) as previously described [18, 19]. In parallel,
soluble fractalkine was administered to the brain via intra-
cerebroventricular (ICV) infusion (200 ng/day) for 3 days
prior to injection of AOM as previously described [18].
This dose was selected to maintain concentrations of
fractalkine in the cerebrospinal fluid at concentrations
that are at or above those reported by other researchers
[20]. Care was taken to minimize the effects of anesthesia
on hepatic metabolism in ICV mice by the following: (1)
all mice were anesthetized with isoflurane to reach sur-
gical plane with the subsequent surgeries taking appro-
ximately 30 min to complete per mouse and (2) AOM
injection was delayed for 3 days after the ICV surgery to
allow for residual anesthesia to be eliminated from the
body. After AOM injection, mice were placed on heating
pads adjusted to 37 °C and monitored for signs of neuro-
logical decline. To reduce the impact of hypoglycemia and
dehydration, cage floors were supplied with hydrogel and
rodent chow and after 12 h and every subsequent 4 h,
mice were injected subcutaneously with 5 % dextrose in
250 μl of saline. If mice underwent a 20 % weight loss or
greater, they were removed from the study.
At 12 h following injection (and every 2 h thereafter),
body temperature, weight, and neurological assessments
were measured. Neurological functioning was assessed by
measuring the pinna reflex, corneal reflex, tail flexion reflex,
escape response reflex, righting reflex, and ataxia which
were scored on a scale of 0 (no reflex) to 2 (intact reflex).
The neurological score at each time point was defined as
the summation of these reflex scores. In addition, time to
coma (defined as a loss of all reflexes) was recorded. Tissue
was flash frozen and collected at coma for further analyses.
Mice used for histochemical studies were transcardially per-
fused with PBS followed by 4 % paraformaldehyde. Whole
brains were removed and placed into 4 % paraformaldehyde
for 24 h, after which they were moved to a 30 % sucrose
solution for cryoprotection. Brains were frozen and sec-
tioned using a cryostat for immunofluorescence imaging.
Cell isolation and flow cytometry
Fresh whole brains from adult C57Bl/6 mice were homo-
genized using an automated homogenizer from Miltenyi
Biotec using solutions provided in the Neural Tissue
Dissociation Kit (Miltenyi Biotec). Following dissociation
into a single-cell suspension, cells were passed through LS
columns (Miltenyi Biotec) containing beads coated with
CD11b antibodies (to isolate microglia) or GLAST anti-
bodies (to isolate astrocytes) localized to the columns. The
remaining cells not bound to the columns were kept as
the neuron-enriched fraction. LS columns were washed to
remove the CD11b-bound cells or the GLAST-bound
cells. Cells were subsequently spun down and homoge-
nized for subsequent experiments.
Liver histology and biochemistry
Paraffin-embedded livers were cut into 3-μm sections
and mounted onto positively charged slides (VWR,
Radnor, PA). Slides were deparaffinized and stained with
Hematoxylin QS (Vector Laboratories, Burlingame, CA)
for 1 min, followed by staining for 1 min with eosin Y
(Amresco, Solon, OH), and rinsed in 95 % ethanol. The
slides were then dipped into 100 % ethanol and sub-
sequently through two xylene washes. Coverslips were
mounted onto the slides using Vectamount mounting media
(Vector Laboratories). The slides were viewed and imaged
using an Olympus BX40 microscope with an Olympus
DP25 imaging system (Olympus, Center Valley, PA).
Serum alanine aminotransferasase (ALT) and bilirubin
were assessed using commercially available kits. Alanine
aminotransferase measurement was performed using a
fluorimetric activity assay. Total bilirubin was assayed
using a total bilirubin ELISA. All assays and subsequent
analyses were performed according to the instructions
provided by the manufacturers.
Real-time PCR
RNA was extracted from flash frozen tissue or isolated
neural cells, and RT-PCR was performed as previously
described using commercially available primers designed
against mouse fractalkine, CX3CR1, and glyceraldehyde
3-phosphate dehydrogenase [21]. A ΔΔCT analysis was
performed using vehicle-treated tissue or isolated cortical
neurons/microglia as controls for subsequent experiments
[22, 23]. Data for all experiments are expressed as mean
relative mRNA levels ± SEM.
Immunofluorescence
Free-floating immunostaining was performed on brain
sections using anti-IBA1 immunoreactivity to detect
morphology and relative staining of microglia. In addition,
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fractalkine and NeuN immunostaining were performed.
Immunoreactivity was visualized using fluorescent second-
ary antibodies labeled with Dylight 488 or Cy3 and counter-
stained with ProLong© Gold Antifade Reagent containing
4′,6-diamidino-2-phenylindole (DAPI). Slides were viewed
and imaged using a Leica Microsystems TCS SP5-X
inverted confocal microscope (Buffalo Grove, IL). Quantifi-
cation of IBA-1 field staining was performed by converting
images to grayscale, inverting their color and quantifying
the number of stained pixels with ImageJ software. The
values for the vehicle group were normalized to 1 with this
reference being used for all other quantifications of IBA1
field staining. Z-stack images were created by performing a
30-μm merge of images through the entire brain section
using ImageJ software.
Cytokine and chemokine ELISAs
Cortex tissue from all treatment groups was homogenized
using a Miltenyi Biotec gentleMACS™ Dissociator, and
total protein was quantified using a Pierce™ BCA Protein
Assay kit (ThermoFisher Scientific, Waltham, MA). Cap-
ture antibodies against CCL2, IL-6, TNFα, or fractalkine
were incubated overnight in 96-well plates. Each ELISA
was performed according to the instructions provided
from R&D Systems, and the total input protein for each
sample was 50 μg. Absorbance was read using a Spectra-
Max® M5 plate reader from Molecular Devices (Sunnyvale,
CA). Data are reported as CCL2, IL-6, TNFα, or fractalk-
ine concentration per milligram of total lysate protein.
Immunoblotting
Immunoblots were performed as previously described [8]
with minor modifications. For western blots, 10 % sodium
dodecyl sulfate-polyacrylamide gel electrophoresis gels
were loaded with 20 μg of protein diluted in Laemmli
buffer. Specific primary antibodies against pERK1/2 and
tERK1/2 were used along with appropriate fluorescent
secondary antibodies (LI-COR, Lincoln, NE). All imaging
was performed using an Odyssey 9120 Infrared Imaging
System (LI-COR). Data are expressed as fold change in
fluorescent band intensity of pERK1/2 divided by tERK1/
2. The values of the vehicle ICV saline group was used as
a baseline and set to a relative protein expression value of
1. All band intensity quantifications were performed using
ImageJ software (National Institutes of Health, Bethesda,
MD). Data for all experiments were expressed as mean
relative protein ± SEM (n = 4).
Statistical analysis
All statistical analyses were performed using Graphpad
Prism software (Graphpad Software, La Jolla, CA). Results
were expressed as mean ± SEM. For data passing norma-
lity tests, significance was established using the Student’s
t test when differences between two groups were analyzed,
and analysis of variance when differences between three
or more groups were compared, followed by the appropri-
ate post hoc test. For neurological score analyses, two-way
analysis of variance analysis and a subsequent Bonferroni
post hoc test were performed. If tests for normality failed,
two groups were compared with a Mann-Whitney U test
or a Kruskal-Wallis ranked analysis when more than two
groups were analyzed. Differences were considered signifi-
cant when the p value was less than 0.05.
Results
Neuronal fractalkine was downregulated following
AOM administration
C57Bl/6 mice were administered the hepatotoxin AOM to
induce acute liver failure and the development of hepatic
encephalopathy. The mouse AOM model of hepatic en-
cephalopathy is characterized by a prodromal phase that
transitions into mild cognitive deficits and quickly pro-
gresses to coma [24]. Fractalkine mRNA expression was
downregulated in AOM-treated mice compared to time-
matched vehicle controls prior to the development of
neurological decline (pre), when minor neurological decline
was evident (minor) and when major neurological decline
was present (major) but had expression similar to controls
when the mice reach coma (Fig. 1a). The expression of
fractalkine was not altered in the vehicle groups over the
time period studied (data not shown); therefore, all vehicle
groups used in the remainder of this study were time-
matched to coma AOM-treated mice. The suppression of
fractalkine mRNA expression observed in AOM-treated
mice correlated with a parallel reduction in fractalkine
protein in cortex lysates throughout AOM-induced neuro-
logical decline (Fig. 1b). The expression of fractalkine has
been reported in multiple cell types in the brain, and there-
fore, immunofluorescence for fractalkine was performed.
This staining demonstrated that the highest expression of
fractalkine was in neurons as a high degree of co-staining
was found with the neuron marker NeuN (Fig. 1c). In order
to determine if AOM treatment led to reduced production
of neuronal fractalkine, neurons were isolated from the
cortex of vehicle and AOM-treated C57Bl/6 mice using im-
munoprecipitation. We have previously utilized this tech-
nique and found that the neuron-enriched cell fraction had
99.7 % of the cells stain positive for CD90, which indicates
that this methodology provides a relatively pure neuron cell
fraction from whole brain homogenates [19]. Fractalkine
mRNA expression was significantly downregulated in
isolated neurons from AOM-treated mice compared to
neurons isolated from vehicle-treated mice (Fig. 1d).
CX3CR1 was downregulated in microglia following
AOM-induced hepatic encephalopathy
Fractalkine transduces its signal through binding CX3CR1,
which has been shown in previous studies to be expressed
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primarily by microglia in the brain [9]. To validate these
studies, the mRNA expression of CX3CR1 was measured
in neurons, astrocytes, and microglia isolated from vehicle-
treated mice. CX3CR1 mRNA expression was significantly
higher in microglia compared to either neurons or astro-
cytes (Fig. 2a). As microglia are the principal cell for
CX3CR1 mRNA expression in the brain, microglia were
isolated from vehicle and AOM-treated mice cortices at
coma using immunoaffinity isolation. This methodology
had previously led to the isolation of a microglia cell frac-
tion where 99.3 % of the cells stained positive for CD11b
[19]. CX3CR1 mRNA expression was found to be signifi-
cantly suppressed in isolated microglia from AOM-treated
mice when compared to isolated microglia from vehicle-
treated mice (Fig. 2b).
Central infusion of soluble fractalkine improved outcomes
of AOM-treated mice
Due to the downregulation of both fractalkine and
CX3CR1 during hepatic encephalopathy, supplementa-
tion of fractalkine could be used to induce this signaling
pathway to help alleviate the pathology associated with
this disease state. ICV infusion of soluble fractalkine was
found to slow the neurological decline that is present
during AOM-induced hepatic encephalopathy with sig-
nificant differences between soluble fractalkine-infused
and saline-infused AOM-treated mice particularly at 20
and 22 h following AOM injection (Fig. 3a). Further-
more, soluble fractalkine-infused mice treated with
AOM took significantly longer to reach coma compared
to AOM-treated mice infused with saline (Fig. 3b). To
Fig. 1 Neuronal fractalkine was downregulated following AOM administration. a Fractalkine mRNA expression in the cortex during the
timecourse of AOM-induced HE with appropriate time-matched tissue analyses from vehicle-treated controls. b Fractalkine concentrations in
cortex lysate normalized to protein concentrations of cortex lysates from vehicle and AOM-treated timecourse mice. c Immunofluorescence
for fractalkine (green) and NeuN (red) with DAPI (blue) used as a nuclear counterstain in vehicle cortex brain tissue. d Fractalkine mRNA
expression in neurons isolated from vehicle-treated and AOM-treated mice cortices. For mRNA expression and fractalkine ELISA analyses,
*p < 0.05 compared to vehicle-treated mice or neurons from vehicle-treated mice, **p < 0.01 compared to vehicle-treated mice. n = 3 for
fractalkine mRNA and ELISA analyses
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see if the neuroprotective protective effect of soluble
fractalkine was due to protective effects on the liver,
assessments of overall liver damage and function were
performed. Hematoxylin and eosin staining in liver sec-
tions from vehicle and AOM-treated mice infused with
fractalkine or saline indicates that the hepatic damage in
AOM-treated mice infused with soluble fractalkine or
saline is similar with significant hepatic necrosis being
present in both groups (Fig. 3c). In order to better assess
overall liver function, bilirubin (Fig. 3d) and ALT (Fig. 3e)
concentrations were measured in serum from vehicle
and AOM-treated mice infused with fractalkine or
saline. The concentrations of both bilirubin and ALT in
AOM-treated mice infused with saline were significantly
higher than vehicle. Interestingly, bilirubin and ALT levels
were significantly reduced in AOM-treated mice infused
with soluble fractalkine when compared to AOM-treated
mice infused with saline indicating that that ICV infusion
of soluble fractalkine may improve liver function. How-
ever, both AOM-treated groups were still significantly
higher than the vehicle-treated groups indicating that liver
damage was still present.
Microglia activation in AOM-treated mice was reduced by
ICV infusion of soluble fractalkine
Determination that soluble fractalkine infusion was
generating an increase in CX3CR1-mediated signaling in
the brain was accomplished by performing immunoblots
for pERK1/2 and tERK1/2 as these proteins are down-
stream effectors of CX3CR1 signaling [25]. In the vehicle-
treated mice, there was no observable difference in cortical
pERK1/2 expression but pERK1/2 was reduced in AOM-
treated ICV saline-infused mice compared to the vehicle-
treated groups and this reduction of pERK1/2 expression
was reversed by ICV soluble fractalkine infusion (Fig. 4a).
As fractalkine has been reported to play a role in neuroin-
flammation, microglia activation was investigated. Microglia
activation and proliferation has been reported in a variety
of neuroinflammatory conditions to include Alzheimer’s
disease and excitotoxic neuronal injury [26, 27]. One
method to assess microglia activation is to determine if
these cells undergo a phenotypic shift from a ramified
resting state to an amoeboid active proinflammatory state.
In order to examine if soluble fractalkine infusion reduces
microglia activation, microglia morphology was assessed in
the cortex of vehicle and AOM-treated mice that were
infused with either soluble fractalkine or saline. Morpho-
logical analysis of microglia using the marker IBA-1 dem-
onstrated that microglia in AOM-treated mice infused with
saline have a larger cell body and retracted processes when
compared to both vehicle-treated groups or AOM-treated
mice infused with soluble fractalkine (Fig. 4b). This suggests
that soluble fractalkine infusion reduced the activation state
of microglia and allowed for microglia to remain in a quies-
cent state. In addition to phenotypic changes in microglia,
neuroinflammation is also characterized by proliferation of
microglia. IBA1 field staining was increased in the cortex of
AOM-treated mice infused with saline, which was reduced
in AOM-treated mice infused with soluble fractalkine
(Fig. 4c). These data support that infusion of soluble frac-
talkine significantly reduced IBA1 staining in AOM-treated
cortex when compared to saline-infused mice (Fig. 4d).
Together, these data support that soluble fractalkine infu-
sion reduced microglia activation and proliferation that
occurs during hepatic encephalopathy.
Elevated cytokine expression observed during hepatic
encephalopathy was reduced via central fractalkine
infusion
Activation of microglia can lead to a variety of responses
with the best characterized being the release of proin-
flammatory cytokines to promote neuroinflammation.
CCL2 is a proinflammatory chemokine involved with the
activation of microglia and has been demonstrated to
Fig. 2 The fractalkine receptor CX3CR1 was downregulated in microglia following AOM-induced hepatic encephalopathy. a CX3CR1 mRNA expression
in isolated neurons, astrocytes, and microglia from vehicle-treated mice with values normalized to CX3CR1 mRNA expression in vehicle neurons.
b CX3CR1 mRNA expression in microglia isolated from the cortex of vehicle and AOM-treated mice. For mRNA analyses, *p < 0.05 compared to
vehicle neurons (a), or microglia from vehicle-treated mice (b), n = 3 for CX3CR1 mRNA analyses
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play a significant role in AOM-induced hepatic encephal-
opathy [8]. Similar to previous studies [8], CCL2 protein ex-
pression was increased in the cortex after AOM treatment
(Fig. 5a). However, pretreatment with soluble fractalkine
attenuated this cortical upregulation of CCL2 expression
(Fig. 5a). Downstream of chemokines are proinflammatory
cytokines with both IL-6 and TNFα playing a significant
role in neuroinflammation. Both IL-6 (Fig. 5b) and TNFα
(Fig. 5c) were found to be elevated in the cortex of AOM-
treated mice infused with saline, but expression of both
cytokines was reduced following soluble fractalkine ICV
infusion in AOM-treated mice. These data support the
concept that soluble fractalkine ICV infusion reduces the
expression of proinflammatory chemokines and cytokines
during AOM-induced HE.
Discussion
Hepatic encephalopathy is a devastating neurological com-
plication of liver disease with few effective treatments;
therefore, the need to identify novel therapeutic targets is
important [28]. Taking this approach, the current study
indicates the role that fractalkine signaling plays in the
progression of hepatic encephalopathy through modulating
microglia activation and subsequent neuroinflammation.
Fig. 3 Soluble fractalkine ICV infusion improved outcomes of AOM-treated mice. a Neurological decline in AOM-treated mice infused ICV with either
saline or soluble fractalkine (sFKN). The neurological score is a summation of assessments for five reflexes and ataxia that indicate a worse neurological
state with a lower score, which is displayed in hours post AOM injection. b Time to coma in hours for AOM-treated mice infused with either saline or
sFKN. c Hematoxylin and eosin staining in liver sections from vehicle or AOM-treated mice infused ICV with saline or sFKN. d Total serum bilirubin
concentrations in vehicle or AOM-treated mice infused with saline or sFKN. e Serum ALT concentrations in vehicle or AOM-treated mice infused ICV
with saline or sFKN. For neurological score and time to coma analyses, *p < 0.05 compared to AOM-treated mice infused with saline. For ALT and
bilirubin assays, *p < 0.05 compared to vehicle-treated ICV saline mice, #p < 0.05 compared to AOM-treated ICV saline mice. n = 4 for all analyses
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Fig. 4 Microglia activation in AOM-treated mice was reduced by ICV infusion of soluble fractalkine. a Representative immunoblot images and
quantification of pERK1/2 and tERK1/2 in cortex lysates from vehicle or AOM-treated mice infused ICV with saline or soluble fractalkine (sFKN).
b Z-stack confocal images of individual microglia stained with IBA1 (red). Microglia when activated become more amoeboid shaped with
retracted cellular processes. c Field staining for IBA1 (red) in the cortex of vehicle or AOM-treated mice infused ICV with saline or sFKN.
d Quantification of IBA1 field staining in the cortex of vehicle or AOM-treated mice infused with saline or sFKN. For quantitative IBA1
immunofluorescence analyses, *p < 0.05 compared to vehicle-treated mice infused with saline, #p < 0.05 compared to AOM-treated
mice infused with saline. n = 4 for immunoblot analyses and n = 10 for IBA1 field quantification analysis
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The results from this study support that (1) fractalkine
and its receptor are downregulated during AOM-induced
neurological decline and (2) supplementing fractalkine
levels directly in the brain reduces neurological decline,
microglia activation, and the expression of proinflamma-
tory cytokines during AOM-induced hepatic encephalo-
pathy. These findings suggest that increasing fractalkine
concentrations, which are suppressed during hepatic
encephalopathy, significantly reduces inflammation and
indicates that fractalkine supplementation may be a
potential treatment strategy for the management of
hepatic encephalopathy.
Fractalkine is a chemokine that is expressed in neurons
in normal physiological conditions, and its suppression dur-
ing neuroinflammatory states contributes to the elevation
of proinflammatory cytokines. Indeed, fractalkine has been
demonstrated to reduce both neurotoxicity and the activa-
tion of microglia in the 6-hydroxydopamine rat model of
Parkinson’s disease [29]. The results from the current study
indicate that during AOM-induced hepatic encephalopathy,
fractalkine is downregulated in the cortex as an early event,
and its expression decreases throughout the duration of this
model until coma is reached. This positions fractalkine
suppression as an early event in the pathogenesis of hepatic
encephalopathy. One of the only other studies investigating
fractalkine expression in the brain during liver pathology
found that rats with partial portal vein ligation had un-
changed fractalkine expression compared to control rats,
though the expression of other chemokines and their re-
ceptors was significantly altered [30]. That being said, this
current report is the first to investigate fractalkine signaling
in overt hepatic encephalopathy due to acute liver failure
and therefore, gaining understanding into fractalkine ex-
pression and signaling during other models, and patients
with hepatic encephalopathy will be required to fully under-
stand the role of this chemokine during this disease state.
In order for fractalkine to generate downstream signal-
ing, this ligand must bind CX3CR1. As microglia are the
Fig. 5 Elevated cytokine expression observed during HE can be reduced via soluble fractalkine infusion. a CCL2 concentrations in the cortex of vehicle
or AOM-treated mice infused with saline or soluble fractalkine (sFKN) normalized for total lysate protein concentration. b Cortical IL-6 levels in vehicle
or AOM-treated mice infused with saline or sFKN normalized for total lysate protein concentration. c TNFα concentrations in the cortex of vehicle
or AOM-treated mice infused with saline or sFKN normalized for total lysate protein concentration. For ELISA analyses *p < 0.05 compared to
vehicle-treated mice infused with saline. n = 3 for all ELISA analyses
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primary source of CX3CR1, the gene expression of this re-
ceptor was assessed in isolated microglia from vehicle and
AOM-treated mice. CX3CR1 mRNA was downregulated
in microglia isolated from the cortices of AOM-treated
mice when compared to control-treated mice. Because of
the technical difficulty and low yield in isolating microglia
from adult mouse brains, analysis of CX3CR1 protein was
not possible in this study. Furthermore, fractalkine, via the
activation of CX3CR1 leads to the downstream phospho-
rylation of ERK1/2. Our data support a suppression of
fractalkine-induced ERK1/2 activation after AOM. Taken
together, our data indicate that the fractalkine/CX3CR1
signaling axis is suppressed as an early event during
AOM-induced hepatic encephalopathy that persists until
coma. A similar suppression of fractalkine signaling has
been reported during various other neuropathies. For
example, during neuroinflammation associated with scra-
pie infection in hamsters, microglia activation occurs and
downregulation of fractalkine and its receptor is observed
[31]. Similarly, in mice with genetic knockout of CX3CR1,
there is reduced expression of IL-1β and TNFα as well as
reduced infarct size following focal cerebral ischemia
compared to wild-type mice [32]. These effects have also
been observed in the clinic, as lower plasma fractalkine
concentrations have been observed in patients who have
worse 6-month outcomes following stroke [33]. Similar
findings regarding fractalkine were observed in the current
study as ICV infusion of soluble fractalkine slowed the
neurological decline and reduced the elevated concentra-
tions CCL2, IL-1β, and TNFα that are associated with
AOM-induced hepatic encephalopathy. That being said,
fractalkine appears to play an immunomodulatory role that
can reduce, but not completely reverse, the pathology of
AOM-treated mice. AOM-induced hepatic encephalopathy
is characterized by elevations of ammonia and bile acids as
a result of liver injury and both of these contribute to the pro-
gression of this disorder [34]. Therefore, fractalkine
supplementation may provide an even greater therapeutic
benefit if used in conjunction with other therapies for the
management of acute liver failure or hepatic encephalopathy.
Contrary to the data reported here, some reports in the
brain, and a few investigating other inflammatory diseases,
suggest that fractalkine can promote the infiltration of
immune cells and generate inflammation. One of these
studies demonstrates that increased fractalkine expression
during experimental autoimmune encephalomyelitis, a
mouse model of multiple sclerosis, promotes lymphocyte
entry into the brain further exacerbating disease severity
[35]. Further support of this is demonstrated in the
α-synuclein-induced inflammation model of Alzheimer’s
disease, where the use of CX3CR1 knockout mice has
been demonstrated to reduce inflammation during this
disease state compared to wild-type mice [13]. These dif-
ferential effects during various neuropathies indicate that
fractalkine signaling may generate different effects depen-
ding on the disease state and the pathology that contributes
to the progression of the disease. Of interest is that
CX3CR1 was initially thought to respond to fractalkine
alone; however, more recently, CX3XR1 was found to also
bind chemokine ligand 26, making the findings using
CX3CR1 knockout mice difficult to interpret with respect
to specific fractalkine signaling [36].
Neuroinflammation has been associated with a variety
of neuropathies including multiple sclerosis, stroke, and
Alzheimer’s disease [37]. In regard to hepatic encepha-
lopathy, microglia activation has been observed during
hepatic devascularization, toxic liver injury, and biliary
cirrhosis [38–40]. Elevations of ammonia occur during
hepatic encephalopathy and have been demonstrated to
promote microglia activation in rats fed an ammonium-
enriched diet indicating that ammonia may generate some
of its effects on hepatic encephalopathy pathogenesis
through exacerbating neuroinflammation [41]. During hep-
atic encephalopathy, microglia activation and subsequent
neuroinflammation is thought to be primarily driven by
increased concentrations of ammonia, lactate, manganese,
or glutamate in the brain [42]. Currently, many of these
effects are not well understood, but recent studies have
begun to expand on how the initiation of neuroinflamma-
tion may occur. Neuroinflammation can be induced by
chemokine signaling, such as through CCL2, which is
upregulated during AOM-induced hepatic encephalopathy
and chemokine receptor 2 or chemokine receptor 4 antag-
onist treatment improved outcomes in AOM-treated mice
[8]. Similar findings were observed during bile duct ligation
in mice where cerebral concentrations of CCL2 were ele-
vated and were associated with monocyte infiltration in the
brain, which was eliminated in CCL2 or chemokine recep-
tor 2 knockout mice [40]. Of interest is that there appears
to be an inverse relationship between CCL2 and fractalkine
during hepatic encephalopathy. Gaining a greater under-
standing of the mechanism that generates these signaling
events may provide better understanding of the initiators of
inflammation during this disease state. This study was the
first to report that supplementing fractalkine during hepatic
encephalopathy suppresses CCL2 concentrations in the
cortex, which indicates that the increase of CCL2 observed
during AOM-induced hepatic encephalopathy is dependent
upon the suppression of fractalkine. Therefore, there is
support that chemokine signaling plays a significant role in
the initiation of inflammation during hepatic encephalo-
pathy, though more studies are needed to fully understand
these signaling pathways and their roles in the pathogenesis
of this disorder.
As AOM-induced hepatic encephalopathy is the result
of acute liver injury, the finding that soluble fractalkine
infusion directly into the brain conferred some protection
to the liver is interesting and unexpected. Due to fractalkine
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being administered directly into the lateral ventricle of the
brain and at a low concentration, one would logically infer
that fractalkine infusion should have little effect on the liver.
Recent studies have identified a variety of findings that
support that this treatment could influence the liver. The
first is that the blood-brain barrier becomes permeable at
the later stages AOM-induced hepatic encephalopathy,
which could allow small amounts of soluble fractalkine to
enter the circulation at the end stages of this model [43].
That being said, fractalkine signaling during liver disease is
generally thought to contribute to hepatic inflammation. In
liver sections from patients with fibrosis and cirrhosis, it
has been reported that hepatic stellate cells upregulate
ADAMs and subsequently lead to the release of soluble
fractalkine that recruits inflammatory cells to the liver and
contributes to increased liver pathology [44]. This contri-
bution to liver injury has also been shown in primary
biliary cirrhosis where fractalkine triggers the infiltration of
CX3CR1 expressing immune cells to the liver that promote
inflammation [45]. Therefore, the protective effects of sol-
uble fractalkine ICV infusion on the liver may be a result of
improved neurological function. The connection between
brain pathology and liver dysfunction is beginning to be-
come recognized as patients with stroke and traumatic
brain injury have elevations of liver enzymes following
injury [46, 47]. That being said, this change in serum trans-
aminases and liver enzymes observed during neuropathies
is not well classified and gaining an understanding of brain-
liver axis signaling will require more studies.
Conclusions
The results presented suggest that following liver failure
and the development of hepatic encephalopathy, fractalk-
ine expression is reduced which contributes to the neuro-
logical decline associated with this disease. Direct cranial
infusion of soluble fractalkine was found to slow neuro-
logical decline, reduce microglia activation, and decrease
the concentrations of proinflammatory cytokines in the
cortex. Therefore, treatments aimed at increasing fractalk-
ine concentrations may be a potential therapeutic strategy
for patients with hepatic encephalopathy.
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